Press Releases

WASHINGTON, Dec. 13, 2019 /PRNewswire/ -- Dr. Gail C. Christopher, executive director of the National Collaborative for Health Equity, today posted an

ALAMEDA, Calif., Dec. 13, 2019 /PRNewswire/ -- Fluxion Biosciences announces the launch of three new targeted NGS liquid biopsy panels: Spotlight Myeloid, Spotlight EGFR, and Spotlight TP53. These new panels complement Fluxion's current pan-cancer panel, Spotlight 59, and have been validated with Fluxion's ERASE-Seq variant caller.The new panels have been lau

FORT WORTH, Texas, Dec. 13, 2019 /PRNewswire/ -- Caregiver Inc. (www.cg-idd.com), an intellectual and developmental disability (I/DD) provider based in Fort Wort

NASHUA, N.H., Dec. 13, 2019 /PRNewswire/ -- Yogibo, a worldwide retailer and designer of next generation furniture and contemporary home décor, is pleased to announce that they are the first certified sensory inclusive retail chain. The project was a collaborative effort with KultureCity. Yogibo is a household name in the autism and sensory community for their uni

DENVER, Dec. 13, 2019 /PRNewswire/ -- Aspen Laser Systems, LLC, an emerging leader in laser therapy, announced the sponsorship and launch of a new program and website "Aspen Las

INCLINE VILLAGE, Nev., Dec. 13, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of its outstanding 2.75% Convertible Senior Notes due in

SAN DIEGO and PENNINGTON, N.J., Dec. 13, 2019 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced interim results from KEYNOTE-890, an ongoing Phase 2 study of TAVO™ (intratumoral IL-12) in combination with KEYTRUDA® (pembrol

MEMPHIS, Tenn., Dec. 13, 2019 /PRNewswire/ -- This year, 26,000 participants from all 50 states and 17 foreign countries  gathered in the Bluff City alongside 40,000 spectators for the 18th annual

MARLBOROUGH, Mass., Dec. 13, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that its 2019 Special Meeting of Stockholders, scheduled for Dec

Participants will learn to identify their emotions and will receive tools to manage them, directly from a group of experts. Registration open here: